Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine/bromelain - Mucpharm

Drug Profile

Acetylcysteine/bromelain - Mucpharm

Alternative Names: BromAc; Bromelain/acetylcysteine - Mucopharm

Latest Information Update: 20 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mucpharm
  • Class Anti-inflammatories; Antibronchitics; Antidotes; Antineoplastics; Cysteine endopeptidases; Expectorants; Mucolytics; Reducing agents; Skin disorder therapies; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors; Glutamate receptor modulators; Mucin inhibitors; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomyxoma peritonei
  • New Molecular Entity No

Highest Development Phases

  • Phase I COVID 2019 infections; Respiration disorders
  • Clinical Phase Unknown Peritoneal cancer
  • Preclinical Adenocarcinoma

Most Recent Events

  • 25 Aug 2022 Mucpharm completes a phase I trial in healthy volunteers for COVID-19 infections (In adults, In the elderly, In volunteers) in Australia (Inhalation, Liquid) (NCT05220605)
  • 08 Feb 2022 Clinical trials in Peritoneal cancer (Intraperitoneal) prior to February 2022 (Mucpharm website, February 2022)
  • 08 Feb 2022 Phase-I clinical trials in Respiration disorders (Inhalation) (Mucpharm website, February 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top